Bertrand Mathon1, Aymeric Amelot2, Karima Mokhtari3, Franck Bielle4. 1. AP-HP, GHU La Pitié-Salpêtrière - Charles Foix, Department of Neurosurgery, F-75013, Paris, France; Sorbonne University, UPMC Univ., Paris 06, F-75005, Paris, France; Brain and Spine Institute (ICM, INSERM, UMRS 1127, CNRS, UMR 7225), Paris, France. Electronic address: bertrand.mathon@aphp.fr. 2. AP-HP, GHU La Pitié-Salpêtrière - Charles Foix, Department of Neurosurgery, F-75013, Paris, France; Sorbonne University, UPMC Univ., Paris 06, F-75005, Paris, France. 3. Brain and Spine Institute (ICM, INSERM, UMRS 1127, CNRS, UMR 7225), Paris, France; AP-HP, GHU La Pitié-Salpêtrière - Charles Foix, Department of Neuropathology, F-75013, Paris, France. 4. Sorbonne University, UPMC Univ., Paris 06, F-75005, Paris, France; Brain and Spine Institute (ICM, INSERM, UMRS 1127, CNRS, UMR 7225), Paris, France; AP-HP, GHU La Pitié-Salpêtrière - Charles Foix, Department of Neuropathology, F-75013, Paris, France.
Abstract
OBJECTIVE: The negative biopsy rate approaches 5% in the literature. In our institution, this rate was 2.6% (42/1638) over a ten-year period (2007-2016). We aimed to assess the diagnostic yield of intraoperative smear during stereotactic biopsies to reduce this negative biopsy rate. PATIENTS AND METHODS: We retrospectively analyzed all consecutive MRI-guided frame-based stereotactic biopsies for which an intraoperative histological smear was carried out, performed over 29 months from January 2017 to May 2019 at the Pitié-Salpêtrière University Hospital (Paris, France). RESULTS: 145 stereotactic biopsies for which an intraoperative histological smear was carried out were performed in 145 adult patients. Mean age at biopsy was 52.4 ± 12.2 years. Histological diagnoses encountered in this series were: primary or secondary cerebral neoplasm (90.3%), inflammatory diseases (4.8%) and infectious diseases (4.8%). All biopsies were contributory to diagnosis. The negative biopsy rate was therefore significantly lower in the patient group for which an intraoperative histological smear was carried out than in our historical control group (0% versus 2.6%, p = 0.04). CONCLUSION: Considering the diagnostic yield benefit contributed by the intraoperative histological smear, we advocate for its routine use during brain stereotactic biopsies.
OBJECTIVE: The negative biopsy rate approaches 5% in the literature. In our institution, this rate was 2.6% (42/1638) over a ten-year period (2007-2016). We aimed to assess the diagnostic yield of intraoperative smear during stereotactic biopsies to reduce this negative biopsy rate. PATIENTS AND METHODS: We retrospectively analyzed all consecutive MRI-guided frame-based stereotactic biopsies for which an intraoperative histological smear was carried out, performed over 29 months from January 2017 to May 2019 at the Pitié-Salpêtrière University Hospital (Paris, France). RESULTS: 145 stereotactic biopsies for which an intraoperative histological smear was carried out were performed in 145 adult patients. Mean age at biopsy was 52.4 ± 12.2 years. Histological diagnoses encountered in this series were: primary or secondary cerebral neoplasm (90.3%), inflammatory diseases (4.8%) and infectious diseases (4.8%). All biopsies were contributory to diagnosis. The negative biopsy rate was therefore significantly lower in the patient group for which an intraoperative histological smear was carried out than in our historical control group (0% versus 2.6%, p = 0.04). CONCLUSION: Considering the diagnostic yield benefit contributed by the intraoperative histological smear, we advocate for its routine use during brain stereotactic biopsies.
Authors: Sophie Katzendobler; Anna Do; Jonathan Weller; Mario M Dorostkar; Nathalie L Albert; Robert Forbrig; Maximilian Niyazi; Rupert Egensperger; Niklas Thon; Joerg Christian Tonn; Stefanie Quach Journal: Front Neurol Date: 2022-03-30 Impact factor: 4.003